Филиппины - английский - FDA (Food And Drug Administration)

marilz pharma'l corp - paracetamol - suspension - 250mg/5ml

Филиппины - английский - FDA (Food And Drug Administration)

interhealthcare pharmaceuticals, inc.; distributor: marilz pharmaceuticals, inc. - omeprazole - capsule - 20 mg

Филиппины - английский - FDA (Food And Drug Administration)

interhealthcare pharmaceuticals, inc.; distributor: marilz pharmaceutical - phenylpropanolamine hydrochloride , chlorphenamine maleate - syrup - 12.5 mg/1 mg per 5 ml

Филиппины - английский - FDA (Food And Drug Administration)

interhealthcare pharmaceuticals, inc.; distributor: marilz pharmaceuticals - phenylpropanolamine hydrochloride , chlorphenamine maleate - syrup (oral drops) - 1.0mg/ 0.8mg per ml

Филиппины - английский - FDA (Food And Drug Administration)

amb hk enterprises inc.; distributor: marilz pharmaceuticals, inc. - cefuroxime (as sodium) - powder for injection (im/iv) - 750mg

Соединенные Штаты - английский - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - indacaterol maleate (unii: 2jec1itx7r) (indacaterol - unii:8or09251mq), glycopyrrolate (unii: v92so9wp2i) (glycopyrronium - unii:a14fb57v1d) - indacaterol 27.5 ug - utibrontm neohaler® is a combination of indacaterol and glycopyrrolate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema. important limitations of use: utibron neohaler is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see warnings and precautions (5.1, 5.2)] . all labas are contraindicated in patients with asthma without use of a long-term asthma control medication [see warnings and precautions (5.1)] . utibron neohaler is not indicated for the treatment of asthma. utibron neohaler is contraindicated in patients who have demonstrated hypersensitivity to indacaterol, glycopyrrolate, or to any of the ingredients [see warnings and precautions (5.5)] . teratogenic effects: pregnancy category c there are no adequate and well-controlled studies with utibron neohaler or its individual components, indacaterol and glycopyrrolate, in pregnant women

Соединенные Штаты - английский - NLM (National Library of Medicine)

ligand pharmaceuticals incorporated - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - capsule, extended release - 30 mg - avinza capsules are a modified-release formulation of morphine sulfate intended for once daily administration indicated for the relief of moderate to severe pain requiring continuous, around-the-clock opioid therapy for an extended period of time. avinza is not intended for use as a prn analgesic. the safety and efficacy of using avinza in the postoperative setting has not been evaluated. avinza is not indicated for postoperative use. if the patient has been receiving the drug prior to surgery, resumption of the pre-surgical dose may be appropriate once the patient is able to take the drug by mouth. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines) avinza is contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product. avinza, like all opioids, is contraindicated in patients with respiratory depression in the absence of resuscitative equipment and in patients with

Соединенные Штаты - английский - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - reclast is indicated for treatment of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, diagnosed by bone mineral density (bmd) or prevalent vertebral fracture, reclast reduces the incidence of fractures (hip, vertebral, and non-vertebral osteoporosis-related fractures). in patients at high risk of fracture, defined as a recent low-trauma hip fracture, reclast reduces the incidence of new clinical fractures [see clinical studies (14.1) ]. reclast is indicated for prevention of osteoporosis in postmenopausal women [see clinical studies (14.2) ]. reclast is indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3 ) ]. reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [s ee clinical

Соединенные Штаты - английский - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - pasireotide (unii: 98h1t17066) (pasireotide - unii:98h1t17066) - pasireotide 0.3 mg in 1 ml - signifor is indicated for the treatment of adult patients with cushing's disease for whom pituitary surgery is not an option or has not been curative. none. risk summary the limited data with signifor in pregnant women are insufficient to inform a drug-associated risk for major birth defects and miscarriage. in embryo-fetal development studies in rabbits, findings indicating developmental delay were observed with subcutaneous administration of pasireotide during organogenesis at doses less than the exposure in humans at the highest recommended dose; maternal toxicity was not observed at this dose (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. data animal data in embryo-fetal development studies in rats given 1, 5, and 10 mg/kg/day subcutaneously throughout organog

Соединенные Штаты - английский - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - panobinostat lactate (unii: hn0t99oo4v) (panobinostat - unii:9647fm7y3z) - panobinostat 10 mg - farydak, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. this indication is approved under accelerated approval based on progression free survival [see clinical studies (14.1)] . continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. none risk summary farydak can cause fetal harm when administered to a pregnant woman. panobinostat was teratogenic in rats and rabbits. if farydak is used during pregnancy or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus. data animal data in embryofetal development studies, panobinostat was administered orally 3 times per week during the period of organogenesis to pregnant rats (30, 100, and 300 mg/kg) and rabbits (10, 40, and 80 mg/kg). i